Sjögren’s syndrome (SS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Sjögren’s syndrome (SS)

Sjögren’s syndrome (SS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030; (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Sjögren’s syndrome (SS) has been reported worldwide in adults and more rarely in children, and there appears to be no racial, or geographic bias in incidence. The disorder, however, has a marked predilection for women and similar to SLE, the female: male ratio is approximately 9:1. According to Thelansis epidemiology study incidence of Sjögren’s syndrome (SS) in US 12.2 per 10,000 and prevalence 3.5 per 10,000. In europe prevalence is reported in ranges from 1.7 to 9.8 cases per 10,000 people.

KOLs insights of Sjögren’s syndrome (SS) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and unmet needs.

Sjögren’s syndrome (SS) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event , Country specific Forecast Model, Market uptake and patient share uptake , Attribute Analysis , Analog Analysis , Disease burden and pricing scenario, Summary and Insights.

S. No        Asset        Company        Partner        Stage

1        Lanraplenib        Gilead Sciences        Ono Pharmaceutical Co. Ltd        Phase 2

2        AMG 557/MEDI5872        MedImmune LLC        Amgen        Phase 2

3        Lacripep         TearSolutions, Inc. Phase 2

4        Parsaclisib         Incyte Corporation Phase 2

5        VIB4920        Viela Bio                Phase 2

6        CFZ533 (iscalimab)        Novartis Pharmaceuticals        Novartis        Phase 2

7        GLPG3970        Galapagos NV                Phase 2

8        SAR441344        Sanofi                Phase 2

9        RSLV-132        Resolve Therapeutics Phase 2

10        Belimumab        GlaxoSmithKline  Phase 2

11        LY3090106        Eli Lilly and Company Phase 1

12        RO5459072        Hoffmann-La Roche Phase 2

13        RC18        RemeGen                Phase 2

14        Abatacept        Bristol-Myers Squibb Phase 3

15        P-552        Parion Sciences                Phase 2

16        S95011        ADIR, a Servier Group company        Servier        Phase 2

17        KCT-0809 ophthalmic solution        Kissei Pharmaceutical Co., Ltd. Phase 3

18        ADX-102 1% Topical Dermal Cream (reproxalap)        Aldeyra Therapeutics, Inc. Phase 3

Read more: Sjögren’s syndrome (SS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030